Request a Quote

Cyprotex strengthen physicochemical profiling services in alliance with Sirius Analytical

Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, and Sirius Analytical Instruments Ltd, leaders in physiochemical profiling, today announce that they have signed a strategic alliance which will allow Cyprotex to offer Sirius Analytical’s physicochemical property services to their customers.

The physicochemical properties of a drug can influence its absorption and distribution into tissues, as well as the drug’s binding characteristics. During the drug discovery process, many prediction technologies heavily rely on measuring certain physical properties of compounds of interest, in particular lipophilicity, pKa and solubility, as they are critical to the drug’s efficacy (activity) and toxicology profile.

Sirius Analytical’s instrumentation is the most reliable and advanced in the market and is routinely used within the industry for physicochemical property determination. The most recent introduction, the SiriusT3, is a fully automated system for rapid and accurate measurement of physicochemical properties using small, often sub-milligram, quantities of material.

Dr. Anthony Baxter, Cyprotex’s Chief Executive Officer, commented: “Physicochemical property determination is key to our understanding of how a drug behaves in the body. The properties are used routinely in prediction methods and feature in our PBPK modelling software, Cloe® PK. Sirius have an impressive record of over 20 years expertise in this specialist field. By partnering with Sirius, Cyprotex customers will have access to a broader range of expert services which complement our existing portfolio of ADME-Tox services.”

Brett Hughes, Chief Executive Officer of Sirius Analytical, added: “We are delighted to begin this strategic partnership with Cyprotex. In the highly competitive contract research space, Cyprotex are renowned for their fast, accurate and professional service, making them an obvious choice of partner for Sirius Analytical. We are looking forward to making our popular PhysChem services even more widely available through our exposure to Cyprotex’s large and growing client portfolio.”

For further information:

Cyprotex PLC Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel

Sirius Analytical Instruments Limited Tel: +44 (0) 1342 820 720
Brett Hughes, Chief Executive Officer

Singer Capital Markets Limited (broker to Cyprotex) Tel: +44 (0) 20 3205 7500
Shaun Dobson
Claes Spang

FTI Consulting Tel: +44 (0) 20 7831 3113
Ben Brewerton
Simon Conway
Mo Noonan

Notes to Editors

About Sirius Analytical Instruments Limited
Established in 1989, Sirius Analytical specialises in the provision of physicochemical instruments, data and consultancy services with facilities in the US and UK. Sirius Analytical specialise in designing and manufacturing unique analytical instrumentation for the pharmaceutical industry. Sirius instruments provide accurate and reliable values for pKa, logP, logD, solubility and dissolution, using methods based on highly automated potentiometric and spectroscopic titration. The ability of New Chemical Entities to cross biological membranes such as the gastro-intestinal tract, blood-brain barrier, skin and cell walls in general, depends on these critical physicochemical parameters. Sirius also offer an analytical service for high quality PhysChem outsourcing, used by hundreds of clients worldwide.

About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683

or fill out the form below:


Download file